Vaccinating Italian infants with a new multicomponent vaccine (Bexsero®) against meningococcal B disease: A cost-effectiveness analysis

References

• Anonychuk A, Woo G, Vyse A, Demarteau N, Tricco AC. The cost and public health burden of invasive meningococcal disease outbreaks: a systematic review. Pharmacoeconomics 2013; 31(7):563-76; PMID:23673904; http://dx.doi.org/10.1007/s40273-013-0057-2
   PubMed Web of Science ®Google Scholar
• Davis KL, Misurski D, Miller J, Karve S. Cost impact of complications in meningococcal disease: evidence from a United States managed care population. Hum Vaccin 2011; 7(4):458-65; PMID:21795848; http://dx.doi.org/10.4161/hv.7.4.14434
   PubMed Web of Science ®Google Scholar
• Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine 2009; 27 Suppl 2:B51-63; PMID:19477562; http://dx.doi.org/10.1016/j.vaccine.2009.04.063
   PubMedGoogle Scholar
• Gasparini R, Panatto D. Meningococcal glycoconjugate vaccines. Hum Vaccin 2011; 7:170-82; PMID:21178398; http://dx.doi.org/10.4161/hv.7.2.13717
   PubMed Web of Science ®Google Scholar
• Panatto D, Amicizia D, Lai PL, Gasparini R. Neisseria meningitidis B vaccines. Expert Rev Vaccines 2011; 10:1337-51; PMID:21919622; http://dx.doi.org/10.1586/erv.11.103
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control: Surveillance of invasive bacterial diseases in Europe 2008/2009. http://www.ecdc.europa.eu. Accessed 2013
   Google Scholar
• Istituto Superiore di Sanità (ISS): Dati di sorveglianza delle malattie batteriche invasive aggiornati al 10/04/2013. http://www.simi.iss.it/dati.htm. Accessed May 2014
   Google Scholar
• ISS-CNESPS: Dati e evidenze disponibili per l'introduzione della vaccinazione anti-meningococco B nei nuovi nati e negli adolescenti. http://www.epicentro.iss.it/temi/vaccinazioni/pdf/Istruttoria%20MENINGOCOCCO%20B.pdf. Accessed September 2015
   Google Scholar
• Finne J, Leinonen M, Mäkelä P. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 1983; 2:355-57; PMID:6135869; http://dx.doi.org/10.1016/S0140-6736(83)90340-9
   PubMed Web of Science ®Google Scholar
• Bjune G, Høiby EA, Grønnesby JK, Arnesen O, Fredriksen JH, Halstensen A, Holten E, Lindbak AK, Nøkleby H, Rosenqvist E, et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 1991; 338:1093-96; PMID:1682541; http://dx.doi.org/10.1016/0140-6736(91)91961-S
   PubMed Web of Science ®Google Scholar
• Sierra GV, Campa HC, Varcacel NM, Garcia IL, Izquierdo PL, Sotolongo PF, Casanueva GV, Rico CO, Rodriguez CR, Terry MH. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann 1991; 14:195-207; PMID:1812432
   PubMedGoogle Scholar
• de Moraes JC, Perkins BA, Camargo MC, Hidalgo NT, Barbosa HA, Sacchi CT, et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet 1992; 340:1074-78; PMID:1357461; http://dx.doi.org/10.1016/0140-6736(92)93086-3
   PubMed Web of Science ®Google Scholar
• Boslego J, Garcia J, Cruz C, Zollinger W, Brandt B, Ruiz S, Martinez M, Arthur J, Underwood P, Silva W. Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Vaccine 1995; 13:821-29; PMID:7483804; http://dx.doi.org/10.1016/0264-410X(94)00037-N
   PubMed Web of Science ®Google Scholar
• Oster P, Lennon D, O'Hallahan J, Mulholland K, Reid S, Martin D. MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 2005; 23(17–18):2191-96; PMID:15755593; http://dx.doi.org/10.1016/j.vaccine.2005.01.063
   PubMed Web of Science ®Google Scholar
• Panatto D, Amicizia D, Lai PL, Cristina ML, Domnich A, Gasparini R. New versus old meningococcal group B vaccines: how the new ones may benefit infants & toddlers. Indian J Med Res 2013; 138(6):835-46; PMID:24521624
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMA): Bexsero. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002333/human_med_001614.jsp&mid=WC0b01ac058001d124. Accessed June 2014
   Google Scholar
• Health Canada: Bexsero. http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/sbd_smd_2014_bexsero_147275-eng.php. Accessed Dec 2014
   Google Scholar
• Australian Government. Department of Health, Therapeutic Goods Administration. ARTG ID 190718. http://search-au.funnelback.com/s/search.html?collection=tga-artg&profile=record&meta_i=190718. Accessed Dec 2014
   Google Scholar
• FDA US. Food and Drug Administration. FDA approves a second vaccine to prevent serogroup B meningococcal disease. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm431370.htm#%2EVMK_tQ3TMfs%2Elinkedin. Accessed Jan 2015
   Google Scholar
• Azzari C, Canessa C, Filippi F, Moriondo M, Indolfi G, Nieddu F, Martini M, de Martino M, Castiglia P, Baldo V, et al. Distribution of invasive meningococcal B disease in Italian pediatric population: implications for vaccination timing. Vaccine 2014; 32:1187-91; PMID:24120548; http://dx.doi.org/10.1016/j.vaccine.2013.09.055
   PubMed Web of Science ®Google Scholar
• WHO: Principles and considerations for adding a vaccine to a national immunization programme From decision to implementation and monitoring. http://www.who.int/immunization/programmes_systems/policies_strategies/vaccine_intro_resources/nvi_guidelines/en/Accessed Oct 2014
   Google Scholar
• Anderson RM, Nokes DJ: Mathematical models of transmission and control. In Holland WW, Detels R, Knox G. Oxford Textbook of Public Health, 2nd Edition. Oxford University Press, New York, 1991. Pp 225-52.
   Google Scholar
• WHO. Laboratory methods for the diagnosis of meningitis caused by Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae. http://www.who.int/csr/resources/publications/meningitis/WHO_CDS_CSR_EDC_99_7_EN/en/. Accessed Aug 2014
   Google Scholar
• Baldovin T, Furlan P, Lazzari R, Cocchio S, Baldo V. Flussi informativi delle meningiti e delle malattie batteriche invasive presenti nella Regione Veneto. http://www.vaccinarsi.org/assets/uploads/news/report_situazione_meningiti_veneto/report_%202007_2012_ssm-simi-mib.pdf. Accessed Sept 2014
   Google Scholar
• Tirani M, Meregaglia M, Melegaro A. Health and economic outcomes of introducing the new MenB vaccine (Bexsero) into the Italian routine infant immunisation programme. Plos One 2015; 10(4):e0123383; PMID:25874805; http://dx.doi.org/10.1371/journal.pone.0123383
   PubMed Web of Science ®Google Scholar
• Tu HA, Deeks SL, Morris SK, Strifler L, Crowcroft N, Jamieson FB, Kwong JC, Coyte PC, Krahn M, Sander B. Economic evaluation of meningococcal serogroup B childhood vaccination in Ontario, Canada. Vaccine 2014; 32(42):5436-46; PMID:25131732; http://dx.doi.org/10.1016/j.vaccine.2014.07.096
   PubMed Web of Science ®Google Scholar
• Christensen H, Hickman M, Edmunds WJ, Trotter CL. Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact. Vaccine 2013; 31:2638-46; PMID:23566946; http://dx.doi.org/10.1016/j.vaccine.2013.03.034
   PubMed Web of Science ®Google Scholar
• Pouwels KB, Hak E, van der Ende A, Christensen H, van den Dobbelsteen GP, Postma MJ. Cost-effectiveness of vaccination against meningococcal B among Dutch infants: Crucial impact of changes in incidence. Hum Vaccin Immunother 2013; 9:1129-38; PMID:23406816; http://dx.doi.org/10.4161/hv.23888
   PubMed Web of Science ®Google Scholar
• Christensen H, Trotter CL, Hickman M, Edmuds WJ. Re-evaluanting cost effectiveness of universal meningitis vaccination (Bexsero) in England: modeling study. BMJ 2014; 349:g5725; PMID:25301037; http://dx.doi.org/10.1136/bmj.g5725
   PubMed Web of Science ®Google Scholar
• di Pietro ML, Capri S, Kheiraoui F, de Waure C, Quaranta G, Poscia A, Specchia ML, Veneziano MA, Di Nardo F, Cadeddu C, et al. Health Technology Assessment della vaccinazione contro Meningococco B. QIJPH 2013; 2:1-113.
   Google Scholar
• WHO – Guide to cost-effectiveness analysis. http://www.who.int/choice/publications/p_2003_generalised_cea.pdf. Accessed on September 2015.
   Google Scholar
• Vogel U, Taha MK, Vazquez JA, Findlow J, Claus H, Stefanelli S, Caugant DA, Kriz P, Abad R, Bambini S, et al. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis 2013; 13:416-25; PMID:23414709; http://dx.doi.org/10.1016/S1473-3099(13)70006-9
   PubMed Web of Science ®Google Scholar
• Frosi G, Biolchi A, Lo Sapio M, Rigat F, Gilchrist S, Lucidarme J, Findlow J, Borrow R, Pizza M, Giuliani MM, et al. Bacterial antibody against a representative epidemiocological meningococcal serogroup B panel confirms that MATS underestimate 4CMenB vaccine strain coverage. Vaccine 2013; 31:4968-74; PMID:23954380; http://dx.doi.org/10.1016/j.vaccine.2013.08.006
   PubMed Web of Science ®Google Scholar
• McQuaid F, Snape MD. Will booster doses be required for serogroup B meningococcal vaccine? Expert Rev Vaccines 2014; 13(3):313-5; PMID:24451002; http://dx.doi.org/10.1586/14760584.2014.878654
   PubMed Web of Science ®Google Scholar
• Gasparini R, Amicizia D, Domnich A, Lai PL, Panatto D. Neisseria meningitidis B vaccines: recent advances and possible immunization policies. Expert Rev Vaccines 2014; 13:345-64; PMID:24476428; http://dx.doi.org/10.1586/14760584.2014.880341
   PubMed Web of Science ®Google Scholar
• Roed C, Omland LH, Engsig FN, Skinhoj P, Obel N. Long-term mortality in patients diagnosed with meningococcal disease: a Danish nationwide cohort study. PloS One 2012; 5:e9662; http://dx.doi.org/10.1371/journal.pone.0009662
   Google Scholar
• Read RC, Baxter D, Chadwick DR, Faust SN, Finn A, Gordon SB, Heath PT, Lewis DJ, Pollard AJ, Turner DP, et al. Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. Lancet 2014; 384:2123-31; PMID:25145775; http://dx.doi.org/10.1016/S0140-6736(14)60842-4
   PubMed Web of Science ®Google Scholar
• Trotter CL, Maiden M. Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs. Expert Rev Vaccines 2009; 8(7):851-61; PMID:19538112; http://dx.doi.org/10.1586/erv.09.48
   PubMed Web of Science ®Google Scholar
• Gasparini R, Comanducci M, Amicizia D, Ansaldi F, Canepa P, Orsi A, Icardi G, Rizzitelli E, De Angelis G, Bambini S, et al. Molecular and serological diversity of Neisseria meningitidis carrier strains isolated from Italian students aged 14 to 22 years. J Clin Microbiol 2014; 52:1901-10; PMID:24648565; http://dx.doi.org/10.1128/JCM.03584-13
   PubMed Web of Science ®Google Scholar
• Muzzi A, Mora M, Pizza M, Rappuoli R, Donati C. Conservation of meningococcal antigens in the genus Neisseria. M Bio 2013; 4:e00163-13; PMID:23760461
   PubMedGoogle Scholar
• Vogel U, Claus H. Vaccine development against Neisseria meningitidis. Microb Biotechnol 2011; 4(1):20-31; PMID:21255369; http://dx.doi.org/10.1111/j.1751-7915.2010.00178.x
   PubMed Web of Science ®Google Scholar
• Ladhani SN, Giuliani MM, Biolchi A, Pizza M, Beebeejaun K, Lucidarme J, Findlow J, Ramsay ME, Borrow R. Effectiveness of Meningococcal B Vaccine against Endemic Hypervirulent Neisseria meningitidis W Strain, England. Emerg Infect Dis 2016; 22(2):309-11; PMID:26811872; http://dx.doi.org/10.3201/eid2202.150369
   PubMed Web of Science ®Google Scholar
• Istituto Nazionale di Statistica (ISTAT): Demografia in cifre. http://demo.istat.it/ Accessed July 2014
   Google Scholar
• Snape M, Dawson T, Oster P, Evans A, John TM, Ohene-Kena B, et al. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr Infect Dis 2010; 29:e71–9; http://dx.doi.org/10.1097/INF.0b013e3181faa6be
   Google Scholar
• Rivaluta: Rivalutazioni e documentazione su prezzi, costi e retribuzioni contrattuali. http://rivaluta.istat.it. Accessed June 2014
   Google Scholar
• AIES. Proposta di line guida per la valutazione economica degli interventi sanitari in Italia PharmacoEconomics – Italian Research Articles 2009; 11(2):83-93.
   Google Scholar
• Capri S, Ceci A, Terranova L, Merlo F, Mantovani L. Guidelines for economic evaluations in Italy: Recommendations from the Italian Group of Pharmacoeconomic Studies. Drug Information J 2001; 35:189-201.
   Web of Science ®Google Scholar
• Circolare del Ministero della Sanità, 400.2/15/5709 del 29 dicembre 1993: Sorveglianza delle meningiti batteriche. http://:www.epicentro.it. Accessed June 2014
   Google Scholar
• SIMI. Malattie batteriche invasive: Protocollo per la sorveglianza nazionale delle malattie invasive da meningococco, pneumococco ed emofilo in Italia. 12/03/2007. http://www.simi.iss.it/meningite_batterica.htm. Accessed July 2014
   Google Scholar
• EUIBIS Invasive Neisseria meningitidis in Europe 2006 Commission of the European communities ECDC Agreement ECD.312. http://www.ecdc.it Accessed July 2014
   Google Scholar
• Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10(5):317-28; PMID:20417414; http://dx.doi.org/10.1016/S1473-3099(10)70048-7
   PubMed Web of Science ®Google Scholar
• Wang B, Haji Ali Afzali H, Marshall H. The inpatient costs and hospital service use associated with invasive meningococcal disease in South Australian children. Vaccine 2014; 32(37):4791-8; PMID:24998605; http://dx.doi.org/10.1016/j.vaccine.2014.05.069
   PubMed Web of Science ®Google Scholar
• Shepard CW, Ortega-Sanchez IR, Scott RD 2nd, Rosenstein NE; ABCs Team. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States. Pediatrics 2005; 115(5):1220-32; PMID:15867028; http://dx.doi.org/10.1542/peds.2004-2514
   PubMed Web of Science ®Google Scholar
• Healy CM, Butler KM, Smith E, Hensey OP, Bate T, Moloney AC, MacMahon P, Cosgrove J, Cafferkey MT. Influence of serogroup on the presentation, course, and outcome of invasive meningococcal disease in children in the Republic of Ireland, 1995-2000. Clin Infect Dis 2002; 34(10):1323-30; PMID:11981727; http://dx.doi.org/10.1086/340050
   PubMed Web of Science ®Google Scholar
• Gottfredsson M, Reynisson IK, Ingvarsson RF, Kristjansdottir H, Nardini MV, Sigurdsson JF, Schneerson R, Robbins JB, Miller MA. Comparative Long-term adverse effects elicited by invasive group B and C meningococcal infections. CID 2011; 53:e117; http://dx.doi.org/10.1093/cid/cir500
   PubMed Web of Science ®Google Scholar
• Viner RM, Booy R, Johnson H, Edmunds WJ, Hudson L, Bedford H, Kaczmarski E, Rajput K, Ramsay M, Christie D. Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study. Lancet Neurol 2012; 11:774-83; PMID:22863608; http://dx.doi.org/10.1016/S1474-4422(12)70180-1
   PubMed Web of Science ®Google Scholar
• van de Beek D. The burden of serogroup B meningococcal disease. Lancet Neurol 2012; 11:743-5; PMID:22863607; http://dx.doi.org/10.1016/S1474-4422(12)70184-9
   PubMed Web of Science ®Google Scholar
• Woods CR. Neisseria meningitidis (Meningococcus). In: Behrman RE, Kliegman RM, Jenson HB, eds. Nelson Textbook of Pediatrics, 17th edition. Philadelphia, PA: Saunders; 2004. pp 896-9.
   Google Scholar
• Brandtzaeg P. Pathogenesis and Pathophysiology of Invasive Meningococcal Disease. In: Frosch M, Maiden MCJ, eds. Handbook of Meningococcal Disease: Infection Biology, Vaccination, Clinical Management. Weinheim, Germany: Wiley-VCH; 2006. Pp 427-80.
   Google Scholar
• Oostenbrink R, A Moll HA, Essink-Bot ML. The EQ-5D and the Health Utilities Index for permanent sequelae after meningitis: a head-to-head comparison. J Clin Epidemiol 2002; 55:791-99; PMID:12384194; http://dx.doi.org/10.1016/S0895-4356(02)00448-1
   PubMed Web of Science ®Google Scholar
• Xu R, Insinga RP, Golden W, Hu XH. EuroQol (EQ-5D) health utility scores for patients with migraine. Qual Life Res 2011; 20:601-08; PMID:21063786; http://dx.doi.org/10.1007/s11136-010-9783-5
   PubMed Web of Science ®Google Scholar
• Saarni SI, Suvisaari J, Sintonen H, Pirkola S, Koskinen S, Aromaa A, Lönnqvist J. Impact of psychiatric disorders on health-related quality of life: general population survey. Br J Psychiatry 2007; 190:326-32; PMID:17401039; http://dx.doi.org/10.1192/bjp.bp.106.025106
   PubMed Web of Science ®Google Scholar
• Caban-Martinez AJ, Lee DJ, Fleming LE, Tancredi DJ, Arheart KL, LeBlanc WG, McCollister KE, Christ SL, Louie GH, Muennig PA. Arthritis, occupational class, and the aging US workforce. Am J Public Health. 2011; 101:1729-34; PMID:21778483; http://dx.doi.org/10.2105/AJPH.2011.300173
   PubMed Web of Science ®Google Scholar
• Stouthard MEA, Essink-Bot ML, Bonsel GJ, Barendregt JJ, Kramers PGN, van der Water HPA, Gunning-Schepers LJ, van der Maas PJ. (1997) Disability weights for disease in The Netherlands. Amsterdan Medical Centre, Institute for Social Health Care, Amsterdam. http://www.moh.govt.nz/notebook/nbbooks.nsf/0/2D7B9CE4FAF56E1ACC256C41000FF92C/$file/Disability%20Weights.pdf. Accessed Sept 2014s
   Google Scholar
• Brown MM, Brown GC, Sharma S, Kistler J, Brown H. Utility values associated with blindness in an adult population. Br J Ophthalmol 2001; 85(3):327-31; PMID:11222340; http://dx.doi.org/10.1136/bjo.85.3.327
   PubMed Web of Science ®Google Scholar
• Donev D, Zalatel-Kragelj, Bjegovic V, Burazeri G. Measuring the burden of disease: Disability Adjusted Life Year (DALY). http://www.mf.uni-lj.si/dokumenti/6b695fc9385e3e2ab8fb41ec7d34660d.pdf Accessed 30 July 2014
   Google Scholar
• Thein HH, Gomes T, Krahn MD, Wodchis WP. Health status utilities and the impact of pressure ulcers in long-term care residents in Ontario. Qual Life Res 2010; 19(1):81-9; PMID:20033300; http://dx.doi.org/10.1007/s11136-009-9563-2
   PubMed Web of Science ®Google Scholar
• Yfantopoulos J. Quality of life and QALYs in themeasurement of health. Arch Hellenic Med 2001; 18(2):114-30.
   Google Scholar
• Wyld M, Morton RL, Hayen A, Howard K, Webster AC. A systematic review and meta-analysis of utility-based quality of life in chronic kidney disease treatments. Plos Med 2012; 9(9):e1001307; PMID:22984353; http://dx.doi.org/10.1371/journal.pmed.1001307
   PubMed Web of Science ®Google Scholar
• Findlow J, Borrow R, Snape MD, Dawson T, Holland A, John TM, et al. Multicenter, open-label, randomized Phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis 2010; 51(5):1127-37; PMID:20954968; http://dx.doi.org/10.1086/656741
   PubMed Web of Science ®Google Scholar
• Giuliani MM, Adu-Bobie J, Comanducci M, Aric∫ B, Savino S, Santini L, Brunelli B, Bambini S, Biolchi A, Capecchi B, et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci U S A 2006; 103:10834-39; PMID:16825336; http://dx.doi.org/10.1073/pnas.0603940103
   PubMed Web of Science ®Google Scholar
• Lucidarme J, Comanducci M, Findlow J, Gray SJ, Kaczmarski EB, Guiver M, Kugelberg E, Vallely PJ, Oster P, Pizza M, et al. Characterization of fHbp, NHBA (gna2132), nadA, porA, sequence type (ST), and genomic presence of IS1301 in group B meningococcal ST269 clonal complex isolates from England and Wales. J Clin Microbiol 2009; 47:3577-85; PMID:19759227; http://dx.doi.org/10.1128/JCM.00936-09
   PubMed Web of Science ®Google Scholar
• Nolan T, O'Ryan M, Wassil J, Abitbol V, Dull P. Vaccination with a multicomponent meningococcal B vaccine in prevention of disease in adolescents and young adults. Vaccine 2015; 33(36):4437-45; PMID:26187261; http://dx.doi.org/10.1016/j.vaccine.2015.06.011
   PubMed Web of Science ®Google Scholar
• Vesikari T, Esposito S, Prymula R, Ypma E, Kohl I, Toneatto D, Dull P, Kimura A, EU Meningococcal B Infant Vaccine Study group. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet 2013; 381(9869):825-35; PMID:23324563; http://dx.doi.org/10.1016/S0140-6736(12)61961-8
   PubMed Web of Science ®Google Scholar
• Santolaya ME, O'Ryan ML, Valenzuela MT, Prado V, Vergara R, Muñoz A, Toneatto D, Graña G, Wang H, Clemens R, Dull PM, V72P10 Meningococcal B Adolescent Vaccine Study group. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet 2012; 379(9816):617; PMID:22260988; http://dx.doi.org/10.1016/S0140-6736(11)61713-3
   PubMed Web of Science ®Google Scholar
• Atkinson W, Wolfe S, Hamborsky J. Epidemiology and prevention of vaccine-preventable diseases. Public Health Foundation 2011.
   Google Scholar
• McQuaid F, Snape MD, John TM, Kelly S, Robinson H, Houlden J, Voysey M, Toneatto D, Kitte C, Dull PM, et al. Persistence of bactericidal antibodies to 5 years of age after immunization with serogroup B meningococcal vaccines at 6, 8, 12 and 40 months of age. Pediatr Infect Dis J 2014; 33:760-66; PMID:24722351; http://dx.doi.org/10.1097/INF.0000000000000327
   PubMed Web of Science ®Google Scholar
• AGENAS. Agenzia Nazionale per i Servizi Sanitari Regionali: Ricoveri ospedalieri. I sistemi tariffari regionali vigenti nell'anno 2009. Gennaio 2010. http://www.quotidianosanita.it/allegati/allegato5477154.pdf Accessed July 2014
   Google Scholar
• ISTAT: retribuzioni. http://www.istat.it/it/archivio/retribuzioni. Accessed July 2014
   Google Scholar
• Gustavsson A, Svensson M, Jacobi F, Allgulander C, Alonso J, Beghi E, Dodel R, Ekman M, Faravelli C, Fratiglioni L, et al. Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 2011; 21:718-79; PMID:21924589; http://dx.doi.org/10.1016/j.euroneuro.2011.08.008
   PubMed Web of Science ®Google Scholar
• Oxford Economic: The economic costs of arthritis for the UK economy. Final Report March 2010. http://www.oxfordeconomics.com/publication/download/222531. Accessed July 2014
   Google Scholar
• Deambrosis P, Terrazzani G, Giusti P, Pullia G. Il costo del paziente depresso: l'esperienza della Ulss 9 di Treviso. Pharmaco Economics Italian Res 2007; 9(1):1-8; http://dx.doi.org/10.1007/BF03320565
   Google Scholar
• Olesen J, Gustavsson A, Svensson M, Wittchen HU, Jönsson B. CDBE2010 study group; European Brain Council. The economic cost of brain disorders in Europe. Eur J Neurol 2012; 19(1):155-62; PMID:22175760; http://dx.doi.org/10.1111/j.1468-1331.2011.03590.x
   PubMed Web of Science ®Google Scholar
• Frick KD, Walt JG, Chiang TH, Doyle JJ, Stern LS, Katz LM, Dolgitser M, Hendlish SK. Direct costs of blindness experienced by patients enrolled in managed care. Ophthalmology 2008; 115:11-7; PMID:17475331; http://dx.doi.org/10.1016/j.ophtha.2007.02.007
   PubMed Web of Science ®Google Scholar
• Guerrini R, Battini R, Ferrari AR, Veggiotti P, Besana D, Gobbi G, Pezzani M, Berta E, Tetto A, Beghi E, et al. The costs of childhood epilepsy in Italy: comparative findings from three health care settings. Epilepsia 2001; 42:641-46; PMID:11380572; http://dx.doi.org/10.1046/j.1528-1157.2001.27300.x
   PubMed Web of Science ®Google Scholar
• Beghi E, Garattini L, Ricci E, Cornago D, Parazzini F. EPICOS Group. Direct cost of medical management of epilepsy among adults in Italy: a prospective cost-of-illness study (EPICOS). Epilepsia 2004; 45:171-8; PMID:14738425; http://dx.doi.org/10.1111/j.0013-9580.2004.14103.x
   PubMed Web of Science ®Google Scholar
• Hepkema H, Pouwels KB, van der Ende A, Westra TA, Postma MJ. Meningococcal serogroup A, C, W-135 and Y conjugated vaccine: a cost-effectiveness analysis in the Netherlands. PLOS One 2013; 8:e65036; PMID:23741448; http://dx.doi.org/10.1371/journal.pone.0065036
   PubMed Web of Science ®Google Scholar
• Gopal I, Bhonagiri S, Ronco C, Bellomo R. Out of hospital outcome and quality of life in survivors of combined acute multiple organ and renal failure treated with continuous venovenous hemofiltration/hemodiafiltration. Intensive Care Med 1997; 23:766-72; PMID:9290991; http://dx.doi.org/10.1007/s001340050407
   PubMed Web of Science ®Google Scholar
• Bloudek LM, Stokes M, Buse DC, Wilcox TK, Lipton RB, Goadsby PJ, Varon SF, Blumenfeld AM, Katsarava Z, Pascual J, et al. Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS). J Headache Pain 2012; 13:361-78; PMID:22644214; http://dx.doi.org/10.1007/s10194-012-0460-7
   PubMed Web of Science ®Google Scholar
• ISTAT: PIL Pro CaPite Italia. http://noi-italia.istat.itindex.php?id7&user_100ind_pi1[id_pagina]=91. Accessed July 2014
   Google Scholar
• ISTAT: Noi Italia 2013 – fecondità. http://www.istat.it/it/archivio/fecondità. Accessed July 2014
   Google Scholar
• ISTAT: Noi Italia 2013 – mercato del lavoro. http://www.istat.it/it/archivio/mercatodellavoro. Accessed July 2014
   Google Scholar
• Decreto Ministeriale - Ministero della Sanità - 5 febbraio 1992. “Approvazione della nuova tabella indicativa delle percentuali d'invalidità per le minorazioni e malattie invalidanti.” Gazz. Uff. 26 febbraio 1992, n. 47, S.O. http://www.gazzettaufficiale.it Accessed July 2014
   Google Scholar
• Landefeld JS, Seskin EP. The economic value of life: linking theory to practice. Am J Public Health 1982; 72:555-66; PMID:6803602; http://dx.doi.org/10.2105/AJPH.72.6.555
   PubMed Web of Science ®Google Scholar
• Cabellos C, Nolla JM, Verdaguer R, Pelegrin I, Ribera A, Ariza J, Viladrich PF. Arthritis related to systemic meningococcal disease: 34 years' experience. Eur J Clin Microbiol Infect Dis 2012; 31:2661-66; PMID:22476361; http://dx.doi.org/10.1007/s10096-012-1610-1
   PubMed Web of Science ®Google Scholar
• Bollettino Ufficiale della Regione Basilicata N5 - 24-2-2014: Parte I. http://:www.basilicatanet.it. Accessed July 2014
   Google Scholar
• Mennini FS, Giorgi Rossi P, Palazzo F, Largeron N. Health and economic impact associated with a quadrivalent HPV vaccine in Italy. Gynecol Oncol 2009; 112:370-6; PMID:19041125; http://dx.doi.org/10.1016/j.ygyno.2008.09.031
   PubMed Web of Science ®Google Scholar
• Tutto sui farmaci. Available: www.torrinomedica.it. Accessed Aug 2014
   Google Scholar
• Gossger N, Snape MD, Yu LM, Finn A, Bona G, Esposito S, Principi N, Diez-Domingo J, Sokal E, Becker B, et al. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA 2012; 307:573-82; PMID:22318278; http://dx.doi.org/10.1001/jama.2012.85
   PubMed Web of Science ®Google Scholar
• Wu FC, Tsang YP. Second-order Monte Carlo uncertainty/variability analysis using correlated model parameters: applications to salmonid embryo survival risk assessment. Ecol Modell 2004; 177(3–4):393-414; http://dx.doi.org/10.1016/j.ecolmodel.2004.02.016
   Web of Science ®Google Scholar
• Fenwick E, O'Brien BJ, Briggs A. Cost-effectiveness acceptability curves-facts, fallacies and frequently asked questions. Health Econ 2004; 13(5):405-15; PMID:15127421; http://dx.doi.org/10.1002/hec.903
   PubMed Web of Science ®Google Scholar